Protalix BioTherapeutics

About

Funding history · 8 rounds · $173.5M total

Headcount over time

Offices

Q&A

What is Protalix BioTherapeutics' primary focus?

Protalix BioTherapeutics is a biopharmaceutical company that develops plant cell-expressed enzyme replacement therapies for rare lysosomal storage disorders.

When did Protalix BioTherapeutics go public on the NYSE?

Protalix BioTherapeutics went public on the NYSE in March 2011.

What is the employee count for Protalix BioTherapeutics?

Protalix BioTherapeutics has 226 employees, falling within the 201-500 employee bucket.

What was the amount raised in Protalix BioTherapeutics' Public Offering in February 2023?

In February 2023, Protalix BioTherapeutics raised $20,000,000 in a Public Offering.

What was the amount raised in Protalix BioTherapeutics' most recent Public Offering in March 2025?

In March 2025, Protalix BioTherapeutics raised $20,000,000 in a Public Offering.

What are the two FDA-approved products developed by Protalix BioTherapeutics?

Protalix BioTherapeutics has two FDA-approved products: Elelyso (taliglucerase alfa) for Gaucher disease and Elfabrio (pegunigalsidase alfa) for Fabry disease.

Which companies does Protalix BioTherapeutics collaborate with?

Protalix BioTherapeutics collaborates with Pfizer Inc. and Chiesi Global Rare Diseases.

When did Protalix BioTherapeutics announce the appointment of Gilad Mamlok as its new Senior Vice President and Chief Financial Officer?

Protalix BioTherapeutics announced the appointment of Gilad Mamlok as its new Senior Vice President and Chief Financial Officer on July 21, 2025.

When did Protalix BioTherapeutics and Secarna Pharmaceuticals enter into a collaboration and option agreement?

Protalix BioTherapeutics and Secarna Pharmaceuticals entered into a collaboration and option agreement on December 17, 2025.

When did Chiesi Global Rare Diseases and Protalix BioTherapeutics receive a positive CHMP opinion for an additional dosing regimen of Elfabrio in the EU?

Chiesi Global Rare Diseases and Protalix BioTherapeutics received a positive CHMP opinion for an additional dosing regimen of every four weeks for Elfabrio (pegunigalsidase alfa) in the EU on January 30, 2026.

Team · 14

Yoseph Shaaltiel

Founder · Board Member & Vice President, Research and Development

Dror Bashan

President & Chief Executive Officer, Director

Gilad Mamlok

Senior Vice President & Chief Financial Officer

Yaron Naos

Senior Vice President, Operations

Ori Kalid

Vice President, Research and Development

Shoshi Tessler

Vice President, Clinical Development & Regulatory Affairs

Tanya Gershanik

Vice President, Quality Affairs

Yael Fellous

Vice President, Human Resources

Eliot Forster

Chairman of the Board of Directors

Amos Bar Shalev

Director

Shmuel “Muli” Ben Zvi

Director

Pol F. Boudes

Director

Christian Elze

Director

Gwen Melincoff

Director

Sectors & technology

Highlights

Tags